Sun, Jul 13, 2014, 9:38 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

The Blackstone Group L.P. Message Board

rrtzrealmd 72 posts  |  Last Activity: Jul 11, 2014 10:41 PM Member since: Aug 24, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • rrtzrealmd by rrtzrealmd Jun 23, 2014 11:03 AM Flag

    ...three little Israeli scams!...four little, five little...well, you get my point...guess what -- I found another one this am!...I think I mentioned DRIO and its antique glucometer sometime previously, and this morning what did I find but a company called -- are you ready for this? -- "Integrity Applications"!!!...HAW!...is that rich or what?!

    ...anyway, IDAP has this marvelous non-invasive glucose monitoring system...unfortunately, they have hardly ANY money -- a million bucks or so -- so getting approvals and marketing are going to be kinda tough...and they also don't have any partners or, for that matter, anyone who appears even remotely interested in partnering...

    ...so, hey, maybe some of you suck...uhhhhhhhhhh..."speculative" investors might wanna bop over there help'em out!...why, heck, I worth they're worth every bit as much as Orascam!...HAW!!!...

  • ...goodness, it seems like every other company I stumble over is an Israeli SCAM!...let's see, a million dollars in cash?...oh, yeah, that'll go a LONG way towards developing and marketing a product!...no partners???...no one even showing an interest in partnering???????...but!...but!!...it's such a "great" device -- massive potential, everyone'll want one!...now, buy my stock -- plueeeeeze!!!...HAW!!!...

  • rrtzrealmd by rrtzrealmd Jun 23, 2014 9:46 AM Flag

    Come on!...with 22 million shares?...market makers getting lazy or what?...

  • Reply to

    Notch Signaling Article 2011

    by stocksifuca Jun 20, 2014 8:53 PM
    rrtzrealmd rrtzrealmd Jun 23, 2014 9:40 AM Flag

    ...I hate to be redundant, but borrowing from my earlier post on the subject, was GSK "naive" when it invested in EXEL's XL228, XL820, and XL844 -- a deal which GSK TERMINATED three years later?...

    ...or was Genentech "naive" when it signed on with EXEL to develop notch inhibitors in 2005?...that's right, norch inhibitors!...by that time EXEL had ALREADY been working on the notch pathway for EIGHT YEARS!...did you know that one of the founders of EXEL -- Dr. Artavanis-Tsakonas -- is one of the big guns in notch research; you can google his name to find his notch lab at Harvard...

    ...after you do that, go over to EXEL's website and read about their current partners...won't see no Genentech...won't see no mention of notch anywhere...but they still got a BUNCH of other partners though...

    ...EXEL even has an APPROVED drug!...yessir, cometriq started on the market in the first quarter of 2013...last quarter EXEL reported revenues of a whopping 4.9 MILLION dollars from cometriq...and GSK gets a whopping THREE per cent of that!...nope, no naivety there!...

    ...were investors "naive" to pay up to $45 (yes, FORTY FIVE dollars) per share back in 2000...were they naive to hold the stock as it steadily sandk over the next fourteeen years?...and were they naive to buy stock in the secondary in January for $8 a share?...only to turn around and see the stock tank to THREE BUCKS only a couple of months later when EXEL announced results of an interim analysis of one of their trials?...

    ...and now any any not naive EXEL shareholder can point proudly to his whopping twenty five CENTS a share in equity while the stock trades at all of $3.50 per share!...ahhhhh, who would've dreamed of such enrichment...

  • ....SCAM biotech!...I swear, these things breed like rabbits, don't they?...HAW!...

  • Reply to

    Notch Signaling Article 2011

    by stocksifuca Jun 20, 2014 8:53 PM
    rrtzrealmd rrtzrealmd Jun 21, 2014 3:55 AM Flag

    ...yeah, I like that one line especially:

    "Although some academics say the entire class of therapeutics should be abandoned, at least one company—OncoMed Pharmaceuticals Inc.—thinks it's still business as usual because the gene knockout data that underpin the new study do not agree with the company's preclinical results."

    ...actually, probably MOST "academics" think the "entire class" should be abandoned...as far as the data "do not agree with the company's preclinical results" -- well, gee, of course not!...how could it?!...that would interfere with OMED's efforts to pull the wool over the eyes of naive investors while milking them for all they're worth!...

  • I only just stumbled across it again. I vaguely remember laughing at it years ago when they said yhey were going to try to get approval to market wellbutrin as a weight loss drug and about fell over laughing...I remember wellbutrin became available as a generic just about the time these clowns went public SEVEN YEARS ago!...

    ...oh, look, and now they're mixing it with zonegran!...well, if mixing it with nalrexone won't work, why not!...if VVUS can get away ith it, why can't we!...HAW!...

    ...hmmmm...that reminds me, I wonder how those shareholder lawsuits against VVUS are working out -- the ones where the shareholders allege "breaches of the fiduciary duty...in connection with the launch of Qsymia...insider trading by some defendants for selling Company stock while purportedly being aware that the Qsymia launch would be less successful than predicted and corporate waste..."...corporate waste?...a biotech --- nawwwwww...HAW!...

    ...huh?...you say OREX already has its own lawsuits:

    "...assert claims for breach of fiduciary duty, waste and unjust enrichment based on, among other things, the alleged grant of stock options to certain officers in excess of the 162(m) Award Limit, repricing stock options allegedly in violation of the Company’s equity incentive plan, the board of directors’ conduct in responding to the May 2013 shareholder demand, and making allegedly false and misleading statements"

    ...awwwwww...unjust enrichment???...come on!...just because management gives itself fat salaries, benefits, bonuses, and perks while producing next to NOTHING for shareholders, no reason to get mean about it!...HAW!...and "false and misleading statements"????...hey, it's a biotech, already!...that comes with the territory, right?...HAW!!!...

  • Reply to

    I had to laugh...

    by rrtzrealmd Jun 13, 2014 10:46 PM
    rrtzrealmd rrtzrealmd Jun 20, 2014 11:17 AM Flag

    "...burned on EXEL..."???...no, I just enjoy showing morons -- like yourself -- how crooked biotechs are...go read my post on HPTX for yet ANOTHER great example...

  • Reply to

    Kinda funny actually...

    by rrtzrealmd Jun 12, 2014 9:28 PM
    rrtzrealmd rrtzrealmd Jun 20, 2014 11:13 AM Flag

    ...oh, look!...a "real" MD responding to bobblehead -- what's not to love!

  • "Notice of exempt offering of securities"?????...hmmmmmmm...13 directors sold 8 MLLION dollars worth of stock?...nice little profit in there I bet!...and coming right after acquiring Andromedscam too!...what a coincidence!

  • Reply to

    About busted a gut laughing!!!

    by rrtzrealmd Jun 19, 2014 9:15 PM
    rrtzrealmd rrtzrealmd Jun 19, 2014 10:19 PM Flag

    Explaining the repurchase of rights, "...Clal Biotech's board of directors audit committee says that Andromeda's buying back of the global rights to DiaPep277 from Teva was "important to accelerate the business development and commercialization and the drug that has taken place in recent months."

    Yeah, right! Like Teva decides to take a 100 million dollar loss because of all the "business development and commercilization" that had "taken place in recent months." How about, those American idiots are buying ANYTHING remotely biotech, so let's see if we can con them as well as we did Aventis and Teva!

    And now, lucky HPTX acquires Andomeda and all rights to diapep277 for the bargain basement price of -- drumroll please -- 20 MILLION dollars!!!

    Talk about a t__d rolling downhill! Why so cheap? Well, first, the autoimmune process can begin YEARS before actual clinical detection of diabetes. Now, for clinical symptoms to develop sufficiently to allow diagnosis, around 90% of the beta cells need to be destroyed. Treating with diascam277 might help preserve some of them, but it won't restore dead beta cells, so you're still insulin dependent, and there's no reason to believe that you won't still be subject to all the same problems every other IDDM patient faces. In other words, you might preserve beta cells, but so what? It's too late!

    And now you understand why Aventis and Teva and pretty much anyone with an IQ larger than a grapenut, walked away from it. Lucky HPTX, huh?

  • Reply to

    About busted a gut laughing!!!

    by rrtzrealmd Jun 19, 2014 9:15 PM
    rrtzrealmd rrtzrealmd Jun 19, 2014 9:32 PM Flag

    In 2004, Peptor merges with "DeveloGen" -- a German biotech -- in order to unite "DeveloGen's efforts to develop treatments for obesity and diabetes with Peptor, whose products also target diabetes and other immune system conditions. The merged firm will develop a wide range of drugs to treat metabolic disease."

    Just THREE years later, in 2007, Develogen "sells" diapep277 to "Andromeda Biotech Ltd. ("Andromeda"), a newly formed wholly owned subsidiary of Clal Biotechnology." I say "sells" because apparently no money changed hands, Develogen just acquired royalties from "future sales" if the drug was ever commercialized.

    In 2009, Teva Pharmaceuticals licenses the drug from Andromeda. Ronny Gal, an ananlyst at Sanford Bernstein estimated " the market for the medicine to be about 50,000 patients a year at a price point of between $5,000 and $10,000 annually. The product is a “nice asset” for Teva, which will probably get 20 percent of sales as a royalty rate."

    In June 2010 Teva Pharmaceutical decided to exercise its option to invest in Andromeda Biotech receiving worldwide exclusive marketing rights to DiaPep277. It eventually would invest 170 MILLION dollars in Andromeda and diapep277 development and trials. The drug was even given orphan drug status by the FDA in 2012. It even completed a phase 3 trial in 2013: "Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients (DIA-AID)"

    Then, in February of 2014, guess what! Andromeda BUYS BACK the rights for a "future payment" of 72 MILLION dollars. Let's see, spend 170 plus million then sell it for a "future" payment of 72 million? What does that tell you?

    Will continue in next post...

  • I only just saw the PR announcing Hyperiscam had bought "Andromeda Biotech"! -- and ISRAELI scam biotech that runs in the same circles as DRIO and ORMP!...

    ...Andromeda lays claim to "DiaPep277" -- geez, even the name sounds like a scam! -- which "is a synthetic peptide of 24 amino acids derived from the sequence of the human heat shock protein 60 (Hsp60). The peptide modulates the immune response that leads to autoimmune diabetes by diminishing or blocking the immunological destruction of beta cells."

    HAW!!! This is just too good!!! So in 1996 a company called "Peptor" is founded in Israel with 63 MILLION dollars in seed money (note to myself -- start a biotech company).

    Then about 20 YEARS ago, they develop this "immunomodulator" and calls it "diapep277." In 2001, they published a paper in Lancet about how it prevents beta cell loss in type 1 diabetics. Lo and behold, in 2002, Aventis pays Peptor 15 MILLION dollars to license the drug for further development and it was described as a "megadeal" by at least one analyst. ONE year later, Aventis RETURNS the drug to Peptor -- no explanation offered but pretty safe to presume they didn't think the drug was worth any further investment.

    I will continue this in another post since Yahoo has decided to limit length for some some reason.

  • Reply to

    I had to laugh...

    by rrtzrealmd Jun 13, 2014 10:46 PM
    rrtzrealmd rrtzrealmd Jun 18, 2014 12:21 AM Flag

    "...why would heavy weights..." ???...you mean kinda like the deal GSK signed with Exelixis back in 2005 to develop XL184, XL281, XL228, XL820, and XL844?...and which GSK TERMINATED three years later?...

    ...or the deal EXEL signed with Genetech to develop notch inhibitors in 2005?...that's right, norch inhibitors!...by that time EXEL had ALREADY been working on the notch pathway for EIGHT YEARS!...did you know that one of the founders of EXEL -- Dr. Artavanis-Tsakonas -- is one of the big guns in notch research; you can google his name to find his notch lab at Harvard...

    ...after you do that, go over to EXEL's website and read about their current partners...won't see no Genentech...won't see no mention of notch anywhere...but they still got a BUNCH of other partners though...

    ...EXEL even has an APPROVED drug!...yessir, cometriq started on the market in the first quarter of 2013...last quarter EXEL reported revenues of a whopping 4.9 MILLION dollars from cometriq...and GSK gets a whopping THREE per cent of that!...whoo-boy!...GSK better build a bigger vault for its loot, huh?...

    ...and where does EXEL trade?...currently around $3.50 a share!...no typo there -- THREE dollars and fifty CENTS per share!...which it reached after a near constant DECLINE from $45 (yes, FORTY FIVE dollars) per share back in 2000...and now an EXEL shareholder can point proudly to his whopping twenty five CENTS a share in equity...ahhhhh, who would've dreamed of such enrichment...

    ....BUT!...did all that success stop EXEL from doing a secondary in January for $8 a share?...why, no!...can't ever have too much cash, right?...but curious how that secondary came just a couple of months before EXEL announced results of an interim analysis of one of their trials, and which resulted in EXEL's stock tanking to three bucks a share...

    ...anyway...did I answer your question, by hte way?

  • Reply to

    CASI = Companion Animal Sciences Institute?

    by retired_retread Jun 17, 2014 7:15 AM
    rrtzrealmd rrtzrealmd Jun 17, 2014 11:10 AM Flag

    ...a "tu_d" by any other name is still a "tu_d"!...insert your own "r" thanks to Yahoo...

  • rrtzrealmd by rrtzrealmd Jun 16, 2014 1:04 AM Flag

    Interesting quote from an article entitled "Notch nicked again" in 2011:

    "When preclinical studies last year suggested that broadly inhibiting signaling through the Notch pathway runs the risk of triggering tumors in endothelial tissue, two companies—Roche's Genentech Inc. unit and Aveo Pharmaceuticals Inc.—tried to sidestep the adverse effects of pan-Notch inhibition by selectively targeting Notch 1. Now, a new paper from Washington University in St. Louis researchers suggests that Notch 1 inhibition may also cause tumors."

    ...and it goes on to say:

    "Although some academics say the entire class of therapeutics should be abandoned, at least one company—OncoMed Pharmaceuticals Inc.—thinks it's still business as usual because the gene knockout data that underpin the new study do not agree with the company's preclinical results."

    ...well, of course not!...you've got a half dozen venture capital funds breathing down your neck to do an IPO so they can rack up a mountain of cash, you darn tootin' that doesn't agree with YOUR preclinical results!

    ...say what:

    “We have shown mechanism-based toxicity,” said Kopan. “It's enough to remove just one receptor—NOTCH1—and you have toxicity. This says that the therapeutic window for drugs that target NOTCH1 is extremely small....“Endothelial cells must have NOTCH1 signaling to prevent them from proliferating uncontrollably,” said Kopan. Thus, he thinks that the findings do not bode well for therapeutics that target NOTCH1.”

    ...dang, somebody wanna shot that sonofagun before he botches our IPO!...

    ...ohhh, not you too:

    "“Notch signaling is one of those pathways that are exceedingly dosage dependent,” said Artavanis-Tsakonas. “If you lose Notch signaling, you change the fate of cells. There's absolutely no doubt that if you start fiddling with Notch signaling there will be consequences."

    I'm tellin'ya it's just a plot to impoverish OMED's management! That''s all! Just ignore all those jokers!

  • Reply to

    I had to laugh...

    by rrtzrealmd Jun 13, 2014 10:46 PM
    rrtzrealmd rrtzrealmd Jun 16, 2014 12:40 AM Flag

    ...well, first, I don't usually use my main email id because posting here seems to attract spam by the truckload...as far as "And in the last 10 years, they were developing products..." -- well, let's all stand up and give OMED a round of slow clapping for all the wonderful "development" they've accomplished...

    ...that said, if you want base your investment decisions on theory and hype, well, God bless you, you go for it!...me, on the other hand, I'm not inclined to buy "pie in the sky" promises...and so far, that's ALL OMED offers...

  • Reply to

    ORMD Sunday jokes!

    by rrtzrealmd Jun 15, 2014 3:03 AM
    rrtzrealmd rrtzrealmd Jun 16, 2014 12:32 AM Flag

    ...first, the stuff will likely be approved -- basically, it's just insulin and while it may have risks, if patients find it useful somehow, then they should have the right to use it...will there be a significant market?...diabetics want an alternative, so maybe, but Mannkind's lack of ANY partners in the past and their recent "pumping" PRs about now "seeking" partners makes me think that big pharma has already looked at it and passed on by...the biggest question is always third party reimbursement -- if insurance, medicare, and medicaid turn thumbs down, then forget it...they, of course, look at cost effectiveness and I don't know enough about the product to assess that...god luck!

  • rrtzrealmd by rrtzrealmd Jun 15, 2014 3:03 AM Flag

    More posters from ORMD on Sunday...a truly dramatic lineup!...first comes the effect of oral insulin variants in PIGS!...well, wahoo!...I'm glad of that because I swear I'm getting tired of wrestling with my diabetic sows!....have you ever tried to give a pig a subcutaneous shot?!...it AIN'T easy, I tell you!...

    ...next comes "bedtime oral insulin"...that's likely the same poster from may 14 that I discussed previously where where they demonstrated their "pill" required 460 units of insulin to lnighttime ower blood sugar a whopping 26 mg/dl...I pointed out that subcutaneous insulin requires only ONE HALF of ONE UNIT to do the same thing ancompared the cost of the two methods -- 50 or so DOLLARS a night for ORMD's nonsense versus about 25 CENTS for SQ insulin...

    ....finally comes something about improved bioavailibility of insulin in soft capsules...what!!!...I thought ORMD had all that bioavailability stuff worked out already!...diabetics were going to be throwing away their needles, it was goin' to be the dawn of a new era!...oh, wait!...I guess now that ORMD's finally CONFESSED as to the HUMONGOUS amount of insulin in their stupid pills and the consequent total lack of any market for them, they need some other excuse to raise money selling stock!...sure!...just cover'em with a little gelatin and that'll fix things...of course, they'll need some money to do the studies, don't you know?...

    ...and the wheels on the biotech bus go round and round, round and round....HAW!

  • Reply to

    I had to laugh...

    by rrtzrealmd Jun 13, 2014 10:46 PM
    rrtzrealmd rrtzrealmd Jun 15, 2014 2:41 AM Flag

    Oh, look, another DA that wants to argue with me...a quick history review:

    Amgen: Founded 1983 -- epogen approved 1989 -- neupogen approved 1991 -- enbrel approved 1998...

    Genentech: Founded 1976 synthetic insulin approved 1982 somatrem approved 1985 activase approved 1987 actimmune approved 1990 nutropin approved 1993 pulmozyme approved 1993 rituxan approved 1997 herceptin approved 1998...plus ten MORE that have been approved since then...

    Oncomed: Founded 2004 Drugs approved NONE Drugs in phase 3 NONE Drugs in Phase 2 NONE

    Timeline for appproval of ANY Oncomed drugs -- what, another TEN YEARS maybe? That is, IF any get approved since the the approval chances are likely one out of a hundred or MORE!

    And all the while management rakes in big salaries, benefits, bonuses, and perks while stockbrokers stuff investor mailboxes with hype, and what do shareholders get? Promises and secondary offerings out the old wazoo!

    Like I said -- and the wheels on the biotech bus go round and round, round and round...

BX
32.27+0.01(+0.03%)Jul 11 4:01 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.